Question explored with the scientific record
Conversation so far
- 1 For anyone with manic depression what is the best recourse for them. + a private exchange
- 2 What about Lithium, levothyroxine, propranolol, escitalopram, Quetiapine + a private exchange
- 3 Is it true that since lithium may damage the thyroid the patient withh bipolar must take a thyroid hormone + a private exchange
- 4 What if the patient has side effects with meds is there any alternative protocol that can be taken that has proven to work + a private exchange
- 5 Which meds are options if I want to avoid weight gain or sleepiness?
- 6 What would be the second best to Lithium and better
- 7 what happens to patients who cannot take any meds for bipolar. What other options doo they have
Answered on this page ↓
what happens to patients who cannot take any meds for bipolar. What other options doo they have
The short version: for a patient who cannot take any standard mood stabilizers, the evidence points to ketamine infusions and ECT as the most studied options, but neither is clean and the long-term data is thin.
The evidence you are asking about is almost entirely about people who can take mood stabilizers. The ketamine trials in the retrieval all studied patients who were already on lithium or valproate [3, 4, 5]. That is a different population from someone who cannot take any meds at all. The Cochrane review found that ketamine's response rate in bipolar depression was about 3 out of 9 patients in one trial and 3 out of 7 in another, compared to zero on placebo [6]. Those are small numbers and short follow-up, 14 days at most. The dissociative side effects are real and may actually predict the antidepressant effect, which means you cannot separate the benefit from the altered state [7].
ECT has better evidence for acute mania. A randomized trial of 50 patients found that bilateral ECT combined with antipsychotics produced remission in about 3.5 sessions, with a mean of 7.6 total treatments [1]. The cognitive side effects were measurable: memory scores dropped about 10 points on the Weschler Memory Scale [1]. That is not trivial. For depression, ultra-brief pulse ECT showed response rates around 78% in both bifrontal and right unilateral placement, with faster response in the unilateral group [2].
| Option | Best evidence for | Response rate | Key side effects | Duration of evidence |
|---|---|---|---|---|
| Ketamine IV 0.5 mg/kg | Bipolar depression (on mood stabilizers) | 33-43% response at 24 hours [5, 6] | Dissociation, blood pressure increase [7] | 14 days max |
| Bilateral ECT | Acute mania | Remission in ~3.5 sessions [1] | Memory decline ~10 points on WMS [1] | Acute phase only |
| Ultra-brief ECT | Bipolar depression | ~78% response [2] | Less cognitive effect than standard ECT [2] | Acute phase only |
The retrieval contains nothing about what happens to bipolar patients who take no medication at all. That is a gap, not a finding. Outside this retrieval, it is well documented that untreated bipolar disorder carries high risks of suicide, hospitalization, and functional decline. But the question is about options for people who cannot take standard drugs, and the evidence here does not answer that directly.
My call: ketamine and ECT are the most studied alternatives, but the evidence comes from patients already on mood stabilizers, the follow-up is short, and the side effects are real. Confidence: low for the specific population you asked about.
Sources used 7
-
Effects of stimulus intensity on the efficacy and safety of twice‐weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial
A randomized, blinded trial in mania comparing threshold versus 2.5x seizure-threshold bilateral electroconvulsive therapy (ECT) found no difference in speed or rate of improvement or remission between the two stimulus intensities, though both were effective and safe.
DOI: 10.1111/j.1399-5618.2009.00668.x -
Randomized comparison of ultra-brief bifrontal and unilateral electroconvulsive therapy for major depression: Clinical efficacy
In a randomized trial of adults with major depressive disorder, ultra-brief bifrontal ECT was compared with ultra-brief right unilateral ECT and found comparable overall efficacy, with faster response in the unilateral group.
DOI: 10.1016/j.jad.2008.11.001 -
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression
In a post-hoc analysis of 36 treatment-resistant bipolar depression patients on lithium or valproate, a single ketamine infusion produced rapid antidepressant effects over 14 days in both anxious and non-anxious subgroups, with no differential disadvantage for the anxious subgro…
DOI: 10.1111/bdi.12277 -
An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder
A secondary exploratory analysis of two double-blind, randomized, placebo-controlled, crossover ketamine trials in treatment-resistant bipolar depression shows that a 0.5 mg/kg IV ketamine infusion rapidly reduces fatigue (as measured by NIH-BFI) compared to placebo, with effect…
DOI: 10.1016/j.jad.2016.01.009 -
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
This study replicates previous findings that a single intravenous infusion of ketamine produces rapid antidepressant effects in patients with bipolar depression, significantly improving depressive symptoms and suicidal ideation within 40 minutes post-infusion.
DOI: 10.1016/j.biopsych.2011.12.010 -
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
This systematic review evaluates the efficacy and acceptability of ketamine and other glutamate receptor modulators for treating depressive symptoms in bipolar disorder, finding limited evidence for ketamine's effectiveness compared to placebo, particularly in terms of response …
DOI: 10.1002/14651858.CD011611.pub2 -
Do the dissociative side effects of ketamine mediate its antidepressant effects?
A secondary data analysis of 108 treatment-resistant depressed inpatients (MDD and bipolar) found that intra-infusion dissociative symptoms predicted greater and more sustained antidepressant response to ketamine, while psychotomimetic effects and vital signs did not.
DOI: 10.1016/j.jad.2014.02.017